Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy

This observational study is tracking the real-world clinical profile and outcomes of patients with severe, uncontrolled asthma in Italy who are receiving tezepelumab — a newer biologic injection treatment that blocks a key inflammatory trigger called TSLP — to understand how the drug performs outside of clinical trial settings. **You may be eligible if...** - You are 12 years old or older - You have been diagnosed with severe, uncontrolled asthma - You are on high-dose inhaled corticosteroids plus a long-acting bronchodilator (with or without additional controller medications) - You received at least one tezepelumab injection between February 2024 and March 2025 under Italian reimbursement guidelines - You signed the informed consent and privacy form **You may NOT be eligible if...** - Your asthma is classified as mild or moderate - You have not received tezepelumab within the study's timeframe - You are under 12 years old - You declined to sign the consent and privacy form Talk to your doctor to see if this trial is right for you.